Companies/US/ARQT

ARCUTIS BIOTHERAPEUTICS, INC.

Income flow

Annual
ARQT 10-K Income StatementPeriod 2025-12-31Source 10-K
ZORYVEFoam$182MZORYVECream0.3$121MZORYVECream0.15$68MZORYVECream0.05$911,000Revenue$376M+91% Y/YGross profit$339M+91% Y/YCost of revenue$37M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$372M
  • ZORYVEFoam$182M48.9%
  • ZORYVECream0.3$121M32.5%
  • ZORYVECream0.15$68M18.4%
  • ZORYVECream0.05$911,0000.2%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).125.7MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).93.8M